Tuberculosis Trials Consortium Clinical Research Services (TBTC) (2020-2030)
Ìý
Project description: RI-MUHC is being awarded for Tuberculosis Trials Consortium (TBTC) from the Centers for Disease Control and Preventions (CDC), Atlanta / United States.
Ìý
The purpose of this procurement is to support clinical trials and clinical research on the treatment, diagnosis and prevention of tuberculosis throughout the ten-year performance period 2020 -2030. Emphasis will be given to studies of latent TB infection in low- and medium- TB incidence settings, inclusive of but not limited to the United States and Canada, as well as studies of active TB disease both domestically and internationally.
Ìý
This is a joint application from an established network of investigators at 8 sub-sites in 4 countries – the CAB-V network (Canada, Australia, Benin and Vietnam) – to participate in the TBTC.
Ìý
Amount award: 13.5 million USD $ (17.2 million CAD $).
Ìý
Agency: Centers for Disease Control and Preventions (CDC), Atlanta / United States.
Ìý
PI: Dr. Dick Menzies / Research team (Chantal Valiquette and Lisandra Lannes).
Ìý
Co-investigators: Menonli Adjobimey (Benin); Marcel Behr (Canada); Sarah Brode (Toronto / Canada); Dina Fisher (Calgary / Canada); Greg Fox (Australia); James Johnston (Vancouver / Canada); Richard Long (Edmonton / Canada); Binh Hoa Nguyen (Vietnam); Faiz Ahmad Khan (Canada), Kevin Schwartzman (Canada); David Zielinski (Canada).
Ìý
Ìý
Ìý
